Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb to present belatacept results

Bristol-Myers Squibb to present belatacept results

29th May 2009

Bristol-Myers Squibb is pleased to share the results of a clinical trial at a major scientific conference, it has stated.

The investigational co-stimulation blocker belatacept will be the subject of nine presentations at the American Transplant Congress, which begins tomorrow (May 30th) and ends June 3rd.

Bristol-Myers Squibb is investigating the compound for its use in solid organ transplantation.

Dr Elliott Sigal is the executive vice-president, chief scientific officer and president of the company’s research and development department.

He stated the business is dedicated to developing innovative therapies to address important unmet medical needs.

“We are pleased to share our belatacept phase III data for the first time at an important scientific conference for transplant professionals,” Dr Sigal commented.

On Wednesday this week (May 27th), Bristol-Myers Squibb presented at the Bernstein Strategic Decisions Conference.

Chairman and chief executive officer Jim Cornelius made a formal speech about the business. An archived edition of the talk is available from the company’s website.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.